There was no association between treatment with candesartan and risk of vascular events ( 17 of 144 [ 11.8 % ] versus 13 of 130 [ 10.0 % ] ; hazard ratio , 1.36 ; 95 % confidence interval , 0.65-2 .83 ; P = 0.41 ) .